X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SHASUN PHARMA VENUS REMEDIES/
SHASUN PHARMA
 
P/E (TTM) x -3.5 123.9 - View Chart
P/BV x 0.1 8.5 1.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   SHASUN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
SHASUN PHARMA
Mar-14
VENUS REMEDIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs12694 133.7%   
Low Rs6146 134.0%   
Sales per share (Unadj.) Rs301.8214.2 140.9%  
Earnings per share (Unadj.) Rs-24.95.3 -466.1%  
Cash flow per share (Unadj.) Rs2.515.8 16.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs293.353.3 549.8%  
Shares outstanding (eoy) m12.3456.62 21.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 94.9%   
Avg P/E ratio x-3.813.1 -28.7%  
P/CF ratio (eoy) x36.74.4 831.6%  
Price / Book Value ratio x0.31.3 24.3%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m1,1543,958 29.2%   
No. of employees `0000.9NA-   
Total wages/salary Rs m3932,164 18.2%   
Avg. sales/employee Rs Th4,026.1NM-  
Avg. wages/employee Rs Th425.0NM-  
Avg. net profit/employee Rs Th-331.8NM-  
INCOME DATA
Net Sales Rs m3,72412,127 30.7%  
Other income Rs m23229 9.8%   
Total revenues Rs m3,74712,356 30.3%   
Gross profit Rs m3951,009 39.1%  
Depreciation Rs m338594 57.0%   
Interest Rs m354415 85.4%   
Profit before tax Rs m-275230 -119.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-73 -43.5%   
Profit after tax Rs m-307302 -101.6%  
Gross profit margin %10.68.3 127.4%  
Effective tax rate %-11.5-31.7 36.3%   
Net profit margin %-8.22.5 -330.8%  
BALANCE SHEET DATA
Current assets Rs m2,6386,884 38.3%   
Current liabilities Rs m2,3058,456 27.3%   
Net working cap to sales %8.9-13.0 -69.0%  
Current ratio x1.10.8 140.6%  
Inventory Days Days13562 219.8%  
Debtors Days Days46108 43.1%  
Net fixed assets Rs m4,8714,970 98.0%   
Share capital Rs m123113 108.9%   
"Free" reserves Rs m3,4962,875 121.6%   
Net worth Rs m3,6193,020 119.8%   
Long term debt Rs m1,3741,817 75.6%   
Total assets Rs m7,50913,347 56.3%  
Interest coverage x0.21.6 14.4%   
Debt to equity ratio x0.40.6 63.1%  
Sales to assets ratio x0.50.9 54.6%   
Return on assets %0.65.4 11.7%  
Return on equity %-8.510.0 -84.8%  
Return on capital %1.613.3 11.9%  
Exports to sales %046.4 0.0%   
Imports to sales %13.914.2 97.4%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m5171,728 29.9%   
Fx inflow Rs m05,843 0.0%   
Fx outflow Rs m5172,173 23.8%   
Net fx Rs m-5173,669 -14.1%   
CASH FLOW
From Operations Rs m514398 129.4%  
From Investments Rs m-123-1,635 7.5%  
From Financial Activity Rs m-3871,309 -29.6%  
Net Cashflow Rs m471 5.9%  

Share Holding

Indian Promoters % 32.9 39.2 83.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.6 5.0%  
FIIs % 0.6 17.6 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 39.6 167.7%  
Shareholders   20,121 20,750 97.0%  
Pledged promoter(s) holding % 36.4 12.3 295.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 150 Points Up; Oil & Gas Stocks Lead(09:30 am)

Asian stock markets are lower today as Japanese and Hong Kong shares show losses. The Nikkei 225 is up 0.3% while the Hang Seng is down 0.1%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 14, 2018 11:49 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - WYETH LTD COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS